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Endothelin receptors (ETA and ETB) are class A GPCRs activated by vasoactive peptide
endothelins, and are involved in blood pressure regulation. ETB-selective signalling induces
vasorelaxation, and thus selective ETB agonists are expected to be utilized for improved anti-
tumour drug delivery and neuroprotection. Here, we report the crystal structures of human
ETB receptor in complex with ETB-selective agonist, endothelin-3 and an ETB-selective
endothelin analogue IRL1620. The structure of the endothelin-3-bound receptor reveals that
the disruption of water-mediated interactions between W6.48 and D2.50 is critical for
receptor activation, while these hydrogen-bonding interactions are partially preserved in the
IRL1620-bound structure. Consistently, functional analysis reveals the partial agonistic effect
of IRL1620. The current findings clarify the detailed molecular mechanism for the coupling
between the orthosteric pocket and the G-protein binding, and the partial agonistic effect of
IRL1620, thus paving the way for the design of improved agonistic drugs targeting ETB.
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Endothelin receptors belong to the class A GPCRs, and areactivated by endothelins, which are 21-amino acid peptideagonists1. Both of the endothelin receptors (the ETA and
ETB receptors) are widely expressed in the human body,
including the vascular endothelium, brain, lung, kidney, and
other circulatory organs2,3. Three kinds of endothelins (ET-1, ET-
2, and ET-3) activate the endothelin receptors (ETRs) with sub-
nanomolar affinities. ET-1 and ET-2 show similar affinities to
both of the endothelin receptors, while ET-3 shows two orders of
magnitude lower affinity to ETA4–6. The stimulation of the ETA
receptor by ET-1 leads to potent and long-lasting vasoconstric-
tion, whereas that of the ETB receptor induces nitric oxide-
mediated vasorelaxation7–9. The human brain contains the
highest density of endothelin receptors, with the ETB receptor
comprising about 90% in areas such as the cerebral cortex10. The
ETB receptor in neurons and astrocytes has been implicated in the
promotion of neuroprotection, including neuronal survival and
reduced apoptosis11,12. Moreover, the ET-3/ETB signalling path-
way has distinct physiological roles, as compared to the ET-1
pathway. In the brain, ET-3 is responsible for salt homeostasis, by
enhancing the sensitivity of the brain sodium-level sensor Nax
channel13. The ET-3/ETB signalling pathway is also related to the
development of neural crest cells, and has an essential role in the
formation of the enteric nervous system14. Thus, mutations of the
ET-3 or ETB genes cause Hirschsprung’s disease, a birth defect in
which nerves are missing from parts of the intestine15,16. Overall,
the endothelin system participates in a wide range of physiolo-
gical functions in the human body.
Since the activation of the ETB receptor has a vasodilating
effect, unlike the ETA receptor, ETB-selective agonists have been
studied as vasodilator drugs for the improvement of tumour drug
delivery, as well as for the treatment of hypertension2,3. IRL1620
(N-Suc-[E9, A11, 15] ET-18–21)17, a truncated peptide analogue of
ET-1, is the smallest agonist that can selectively stimulate the ETB
receptor, and currently no non-peptidic ETB-selective agonists
have been developed. The affinity of IRL1620 to the ETB receptor
is comparable to that of ET-1, whereas it essentially does not
activate the ETA receptor, and thus it shows high ETB selectivity
of over 100,000-fold. Due to its large molecular weight, IRL1620
is not orally active and thus requires intravenous delivery. Despite
its pharmacokinetic disadvantages, IRL1620 is an attractive can-
didate for the treatment of various diseases related to the ETB
receptor. Since the ETB-selective signal improves blood flow,
IRL1620 could be utilized for the improved efficacy of anti-cancer
drugs by increasing the efficiency of drug delivery, as shown in rat
models of prostate and breast cancer18–21. Moreover, this strategy
can also be applied to radiotherapy in the treatment of solid
tumours, as the radiation-induced reduction in the tumour
volume was enhanced by IRL162022. IRL1620 also has vasodila-
tion and neuroprotection effects in the brain. IRL1620 reduced
neurological damage following permanent middle cerebral artery
occlusion in a rat model of focal ischaemic stroke23. Moreover,
the stimulation of the ETB receptor by IRL1620 reduces the
cognitive impairment induced by beta amyloid (1-40), a patho-
logical hallmark of Alzheimer’s disease, in rat experiments24,25.
These data suggest that ETB selective agonists might offer new
therapeutic strategies for neuroprotection and Alzheimer’s dis-
ease. The safety and maximal dose of IRL1620 were investigated
in a phase I study. While a recent phase 2 study of IRL1620 in
combination with docetaxel as the second-line drug reported no
significant improvement in the treatment of advanced biliary
tract cancer (ABTC)26, further trials for selected patients based on
tumour types with various choices for the second-line drugs are
still expected. Concurrently, the pharmacological properties of
IRL1620 could also be improved for better clinical applications.
However, little is known about the selectivity and activation
mechanism of this artificially designed agonist peptide, although
the ETB structures in complex with ET-1 and antagonists have
been determined27,28.
In this study, we report the crystal structures of the ETB
receptor in complex with two ETB-selective ET variant agonists,
ET-3 and IRL1620. Together with their detailed pharmacological
characterization, the structures reveal the different activation
mechanisms of these agonists, especially for the partial activation
by IRL1620.
Results
Functional characterization of ET-3 and IRL1620. We first
investigated the biochemical activities of ET-3 and IRL1620 for
the human endothelin receptors, by TGFα shedding (G-protein
activation, specifically the Gq and the G12 families) and β-arrestin
recruitment assays. The EC50 and Emax values of ET-3 for the ETB
receptor were similar to those of ET-1 in both assays, while the
EC50 value for ETA was about 5-fold lower (Fig. 1a, b, and
Table 1, Table 2). These data indicate that ET-3 functions as a full
agonist for the endothelin receptors, with moderate ETB-selec-
tivity. The EC50 values of IRL1620 for the ETB receptor were
almost the same as those of ET-1 in both assays. In contrast, a
320 nM concentration of IRL1620 did not activate ETA in the
TGFα shedding assay (Fig. 1a). These data showed that IRL1620
is ETB-selective by over 3000-fold, in excellent agreement with
previous functional analyses17,29. However, despite its sub-
nanomolar affinity, the Emax values of IRL1620 for the ETB
receptor were 88% (TGFα shedding assay) and 87% (β-arrestin
recruitment assay) of the Emax value of ET-1 (Table 1 and 2),
indicating that IRL1620 functions as a partial agonist for the ETB
receptor.
To obtain mechanistic insights into the different actions of
these agonists, we performed X-ray crystal structural analyses of
the human ETB receptor in complex with ET-3 and IRL1620. For
crystallization, we used the previously established, thermostabi-
lized ETB receptor (ETB-Y5)27,30. IRL1620 also functions as a
partial agonist for the thermostabilized receptor, as the Emax
values for ETB-Y5 were lower than those of ET-1 in both assays
(84% and 85% in the TGFα shedding assay and the β-arrestin
recruitment assay, respectively), while the EC50 values of IRL1620
were increased for ETB-Y5 by about 9- and 6-fold in the TGFα
shedding assay and β-arrestin recruitment assay, respectively, as
compared to the wild type receptor (Fig. 1a, b middle and
Tables 1, 2). To facilitate crystallization, we replaced the third
intracellular loop (ICL3) of the receptor with T4 Lysozyme (ETB-
Y5-T4L), and using in meso crystallization, we obtained crystals
of ETB-Y5-T4L in complex with ET-3 and IRL1620 (Supplemen-
tary Figure 1a, b). In total, 757 and 68 datasets were collected for
the ET-3- and IRL1620-bound receptors, respectively, and
merged by the data processing system KAMO31. Eventually, we
determined the ETB structures in complex with ET-3 and
IRL1620 at 2.0 and 2.7 Å resolutions, respectively, by molecular
replacement using the ET-1-bound receptor (PDB 5GLH)
(Table 3). The datasets for the ET-3 bound receptor were mainly
collected with an automated data-collection system, ZOO, which
allowed the convenient collection of a large number of datasets.
The electron densities for the agonists in both structures were
clearly observed in the Fo− Fc omit maps (Supplementary
Figure 1c, d).
ETB structure in complex with the full agonist ET-3. We first
describe the ETB structure in complex with ET-3. The overall
structure consists of the canonical 7 transmembrane helices
(TM), the amphipathic helix 8 at the C-terminus (H8), two
antiparallel β-strands in the extracellular loop 2 (ECL2), and the
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Fig. 1 Pharmacological characterizations of ET-3 and IRL1620. a Concentration-response curves of AP-TGFα release in the ET-1, ET-3, and IRL1620
treatments of HEK293 cells expressing the indicated endothelin receptors. Symbols and error bars are means and s.e.m. (standard error of the mean) of
five or seven independent experiments, each performed in triplicate. Note that the error bars are smaller than the symbols for most data points. b
Concentration–response curves of β-arrestin recruitment in the ET-1, ET-3, and IRL1620 treatments of HEK293 cells expressing the endothelin receptors.
Symbols and error bars are means and s.e.m. of four independent experiments, each performed in duplicate
Table 1 TGFα shedding assay
ETB (n= 7) ETB-Y5 (n= 7) ETA (n= 5)
Ligand EC50, nM (pEC50 ±
SEM)
Emax ± SEM, % EC50, nM (pEC50 ±
SEM)
Emax ± SEM, % EC50, nM (pEC50 ±
SEM)
Emax ± SEM, %
ET-1 0.11 (9.94 ± 0.04) 100 0.099 (10.01 ± 0.07) 100 0.13 (9.89 ± 0.04) 100
ET-3 0.13 (9.89 ± 0.04) 100.5 ± 0.6 (NS) 0.077 (10.12 ± 0.06) 100.9 ± 0.3 (NS) 0.65 (9.19 ± 0.03) 101.2 ± 0.8 (NS)
IRL1620 0.11 (9.97 ± 0.03) 87.6 ± 1.0*** 0.92 (9.04 ± 0.04) 83.6 ± 1.4*** NA NA
The EC50 and Emax values of the AP-TGFα release response for the endothelin receptors. The Emax value of the AP-TGFα release response in the ET-1 treatment was normalized to 100% for each
experiment. Emax values that significantly differ from the wild-type are denoted by asterisks
*** P < 0.001 as compared with ET-1, one-way ANOVA with Dunnett’s post hoc test
NS Not significant. NA Parameters not available owing to lack of responses
Table 2 β-Arrestin recruitment assay
ETB (n= 4) ETB (n= 4) ETA (n= 4)
Ligand EC50, nM (pEC50 ±
SEM)
Emax ± SEM, % EC50, nM (pEC50 ±
SEM)
Emax ± SEM, % EC50, nM (pEC50 ±
SEM)
Emax ± SEM, %
ET-1 2.7 (8.56 ± 0.02): 100 3.3 (8.48 ± 0.02) 100 2.3 (8.63 ± 0.05) 100
ET-3 3.3 (8.49 ± 0.03) 104.8 ± 0.5 (NS) 3.5 (8.46 ± 0.02) 104.8 ± 0.5 (NS) 10.8 (7.97 ± 0.05) 81.1 ± 0.7***
IRL1620 3.1 (8.51 ± 0.05) 87.3 ± 2.7*** 15.1 (7.82 ± 0.08) 85.4 ± 3.3*** NA NA
The EC50 and Emax values of the β-arrestin recruitment for the endothelin receptors. The Emax value of the β-arrestin recruitment in the ET-1 treatment was normalized to 100% for each experiment. Emax
values that significantly differ from the wild-type are denoted by asterisks
***P < 0.001 as compared with ET-1, one-way ANOVA with Dunnett’s post hoc test
NS Not significant. NA Parameters not available owing to lack of responses
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N-terminus that is anchored to TM7 by a disulfide bond (Fig. 2b),
and is similar to the previous ET-1-bound structure27 (overall R.
M.S.D of 1.0 Å for the Cα atoms) (Fig. 2c). Similar to ET-1, ET-3
adopts a bicyclic architecture comprising the N-terminal region
(residues 1–7), the α-helical region (residues 8–17), and the C-
terminal region (residues 18–21), and the N-terminal region is
attached to the central α-helical region by the intrachain disulfide
bond pairs (C1–C15 and C3–C11). The amino acid residues of
the α-helical and C-terminal regions are highly conserved
between ET-1 and ET-3 (Fig. 2a), and the agonist peptides
superimposed well (Fig. 2c, d and Supplementary Figure 2a–d).
Accordingly, these regions form similar interactions with the
receptor in both structures (Supplementary Figure 3a, b). In
contrast, all of the residues, except for the disulfide bond-forming
C1 and C3, are replaced with bulkier residues in ET-3 (Fig. 2a).
Despite these sequence differences, the N-terminal regions are
similarly accommodated in the orthosteric pocket in both struc-
tures, because these bulky residues are exposed to the solvent and
interact poorly with the receptor (Fig. 2d). These structural fea-
tures explain the similar high affinity binding of ET-3 to the ETB
receptor, as compared with ET-1.
Previous studies demonstrated that the N-terminal residues of
the ETB receptor have a critical role in the virtually irreversible
binding of the endothelins32. As in the ET-1-bound structure, the
N-terminal tail is anchored to TM7 via a disulfide bond between
C90 and C358 in the ET-3-bound structure, constituting a lid that
prevents agonist dissociation. The high-resolution ET-3-bound
structure allowed more accurate tracing of the elongated N-
terminal residues (Fig. 2e, f, and Supplementary Figure 1e), as
compared with the ET-1-bound structure, and revealed more
extensive interactions with the agonist peptide. P88, I94,
Y247ECL2, and K248ECL2 form a lid over ET-3, which is stabilized
by a water-mediated hydrogen bonding network among the
carbonyl oxygen of P93, the side chains of Y247ECL2 and
K248ECL2, and D8 of ET-3 (Fig. 2e). In addition, three
consecutive prolines (P87, 88, 89) stretch over the N-terminal
region of ET-3, and two of them form van der Waals interactions
with ET-3. Moreover, ECL1, 2 and the N-terminal residues form
an extended water-mediated hydrogen bonding network over ET-
3. These extensive interactions strongly prevent the agonist
dissociation.
ETB structure in complex with the partial agonist IRL1620.
Next we describe the ETB structure in complex with the partial
agonist IRL1620, a linear peptide analogue of ET-117 (Fig. 3a).
Previous mutant and structural studies revealed that the N-
terminal region contributes to the stability of the overall bicyclic
structure by the intramolecular disulfide bonds, and thus facil-
itates the receptor interaction17,27,33. IRL1620 completely lacks
the N-terminal region, and consists of only the α-helical and C-
terminal regions (Fig. 3b). Two cysteines in the α-helical region
are replaced with alanines, and negative charges are introduced
into the N-terminal end of the helix, by replacing lysine with
glutamic acid (E9) and modifying the N-terminal amide group
with a succinyl group (Fig. 3c). The consequent cluster of negative
charges on the N-terminal end of IRL1620 (succinyl group, D8,
E9, and E10) reportedly has an essential role in IRL1620 binding
to the ETB receptor17. This cluster electrostatically complements
the positively charged ETB receptor pocket, which includes
K3466.58 and R357ECL3 (Fig. 3d). Moreover, this negative cluster
probably stabilizes the α-helical conformation of IRL1620, by
forming a hydrogen-bonding cap at the N-terminally exposed
amines34. Due to these effects, IRL1620 adopts a similar helical
conformation, even without the intramolecular disulfide bonds
(Supplementary Figure 2c, d), and forms essentially similar
interactions with the receptor, as compared with the endogenous
agonists, ET-1 and ET-3 (Supplementary Figure 3a–c). These
structural features are consistent with the high affinity of IRL1620
to the ETB receptor, which is comparable to those of ET-1 and
ET-3 (Fig. 1a, b). Nevertheless, the N-terminal side of the α-
helical region of IRL1620 is less visualized in the electron density,
suggesting its higher flexibility as compared to those of ET-1 and
ET-3 (Supplementary Figure 1d), probably due to the lack of the
N-terminal region. In contrast to the quasi-irreversible binding of
ET-1, IRL1620 binding is reportedly reversible35. Such structural
differences may account for the different dissociation properties
of these agonists.
IRL1620 does not bind to the ETA receptor at all in the same
concentration range, confirming its high selectivity for the ETB
receptor (Fig. 1a, b, and Table 1 and 2). To elucidate the
mechanism of this selectivity, we compared the amino acid
compositions of the IRL1620 binding sites between the ETB and
ETA receptors (Fig. 4a and Supplementary Figure 4). While the
transmembrane region is highly conserved, the residues in ECL2
are diverse. In particular, the hydrophobic residues L252 ECL2 and
I254 ECL2 are replaced with the polar residues H236 and T238 in
the ETA receptor, respectively (Fig. 4a, b). These residues form
extensive hydrophobic interactions with the middle part of
IRL1620. However, the double mutation of L252H and I254T
only reduced the potency of IRL1620 by 2-fold in the TGFα
shedding assay (Fig. 4c and Table 4), suggesting that these
residues are not the sole determinants for the receptor selectivity
of IRL1620. Therefore, we focused on other residues of ECL2. In
the ETB receptor, P259ECL2 and V260ECL2 generate a short kink
Table 3 Data collection and refinement statistics
ET-3 IRL1620
Data collection
Space group C2221 C2221
Cell dimensions
a, b, c (Å) 65.5, 172.3, 121.3 100.0, 303.9, 60.2
α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å)a 50–2.00 (2.12–2.00) 50–2.70 (2.80–2.70)
Rmeasa 0.860 (18.057) 0.499 (5.826)
Rpima 0.060 (1.277) 0.108 (1.250)
<I/σ(I)>a 20.7 (0.95) 9.0 (1.4)
CC1/2a 0.998 (0.559) 0.981 (0.382)
Completeness (%)a 100.0 (100.0) 99.99 (100.0)
Redundancya 204.6 (199.2) 21.5 (21.5)
Refinement
Resolution (Å) 50–2.00 50–2.70













Bond lengths (Å) 0.007 0.002
Bond angles (°) 0.862 0.517
Ramachandran plot
Favoured (%) 98.6 97.3
Allowed (%) 1.2 2.5
Outlier (%) 0.2 0.2
aValues in parentheses are for highest-resolution shell
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on the loop between the β-strand and TM5, but the ETA receptor
has a truncated loop region and completely lacks these residues
(Fig. 4a). In addition, the ETA receptor has a proline (P228) in the
first half of ECL2, which should disturb the β-strand formation as
in the ETB receptor (Fig. 4b). These observations suggest that
ECL2 adopts completely different structures between the ETA and
ETB receptors. Moreover, ECL1 is also different between the two
















Fig. 2 ETB structure in complex with ET-3. a Comparison of the amino acid sequences of ET-1 and ET-3. b The overall structure of the ET-3-bound ETB
receptor. The receptor is shown as an orange-red ribbon model. ET-3 is shown as a transparent surface representation and a ribbon model, with its N-
terminal region coloured cyan, α-helical region orange, and C-terminal region deep pink. The side chains of ET-3 are shown as sticks. c, d Superimposition
of the ET-3 and ET-1-bound ETB receptors, coloured orange-red and green, respectively, viewed from the membrane plane (c), and from the extracellular
side (d). The side chains of ET-1 and ET-3 are shown as sticks. e, f Comparison of the interactions in the ET-1- (e) and ET-3- (f) bound structures. The
receptors are shown as transparent surface representations and ribbon models. Endothelins are shown as ribbon models. The residues involved in the
irreversible binding of the endothelins are shown as sticks
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compared to the ETB receptor (Supplementary Figure 4). Since
ECL1 interacts with the β-strands in ECL2 (Fig. 4a), this
elongation could affect the orientation of the β-strands. Overall,
the sequence divergences in the extracellular loops suggest that
the ETA and ETB receptors have different extracellular archi-
tectures in these regions, which may account for their different
selectivities for the isopeptides.
Receptor activation and partial activation. To elucidate the
mechanism of the partial activation by IRL1620, we compared the
IRL1620-bound structure with the full-agonist ET-3-bound
structure (Fig. 5). IRL1620 forms essentially similar receptor
interactions to those of the α-helical and C-terminal regions of
ET-3 (Supplementary Figure 5a, b). The intracellular portions of
the receptors are quite similar between the ET-3- and IRL1620-
bound structures, in which TM7 and H8 adopt active conforma-
tions, while the remaining parts of the receptors still represent the
inactive conformation of GPCRs (Fig. 5a, and Supplementary
Figure 6). On the extracellular side, IRL1620 induces similar
conformational changes to those observed in the ET-1- and ET-3-
bound structures; namely, the large inward motions of TM2, 6,
and 7, which are critical for receptor activation (Fig. 5b, c).
However, the extent of the inward motion of TM6-7 is smaller by
about 1 Å in the IRL1620-bound structure, as compared with that
in the ET-3-bound structure, due to the different ligand archi-
tectures between IRL1620 and ET-3. Since IRL1620 lacks the N-
terminal region, the orthosteric pocket of the receptor has more
space, and consequently the α-helical region of IRL1620 is tilted
differently toward TM6 (Fig. 5b). In addition, while the N-
terminal region of ET-3 interacts with TM6 of the receptor, by
forming a hydrogen bond between the carbonyl oxygen of T2 and
K3466.58 (superscripts indicate Ballesteros–Weinstein numbers),
IRL1620 lacks this interaction, resulting in the different orienta-
tion of TM6-7. As TM6 has an especially important role for the
cytoplasmic G-protein binding, this difference is probably related




















Fig. 3 ETB structure in complex with IRL1620. a Comparison of the amino acid sequences of ET-1 and IRL1620. b The overall structure of the IRL1620-bound
ETB receptor. The receptor is shown as an orange ribbon model. IRL1620 is shown as a transparent surface representation and a ribbon model, with the α-
helical and C-terminal regions coloured orange and deep pink, respectively. c Superimposition of the IRL1620- and ET-1-bound receptors viewed from the
membrane plane, coloured orange and green, respectively. The ETB receptors and agonists are shown as ribbon models. The different residues between ET-
1 and IRL1620 are shown as sticks. d Electrostatic surfaces of the IRL1620-bound ETB structure. The negatively charged moieties on the N-terminal end of
IRL1620 and the positively charged residues in the extracellular side of TMs 6 and 7 are shown as sticks
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A comparison of the intermembrane parts revealed further
differences in the allosteric coupling between the orthosteric
pocket and the intermembrane part. Previous studies have shown
that the agonist binding induces the disruption of the hydrogen-
bonding network around D1472.50, which connects TMs 2, 3, 6,
and 7 and stabilizes the inactive conformation of the ETB
receptor28 (Supplementary Figure 7a). The present high-
resolution ET-3-bound structure provides a precise mechanistic
understanding of this rearrangement (Fig. 5d, and Supplementary
Figure 7b). In particular, the water-mediated hydrogen bonds
involving D1472.50, W3366.48, and N3787.45 in the inactive
conformation collapse upon ET-3 binding, by the inward motions
of TMs 2, 6, and 7. The W3366.48 side chain moves downward by
about 2.5 Å, resulting in the disruption of the water-mediated
hydrogen bond with D1472.50, and consequently, the D1472.50
side chain moves downward by about 3 Å and forms hydrogen
bonds with the N3827.49 and N1191.50 side chains. The N3787.45
side chain also moves downward by about 1.5 Å and forms a
hydrogen bond with the nitrogen atom of the W3366.48 side
chain. The downward movements of the W3366.48 and N3787.45
side chains consequently induce the outward repositioning of the
F3326.44 side chain and the middle part of TM6, by about 1 Å.
W6.48 and F6.44 are considered to be the transmission switch of
the class A GPCRs, which transmits the agonist-induced motions
to the cytoplasmic G-protein coupling interface. Overall, our
results show that the collapse of the water-mediated hydrogen-
bonding network involving D1472.50, W3366.48, and N3787.45
propagates as the structural change in the transmission switch,
and probably induces the outward displacement of the cytoplas-
mic portion of TM6 upon G-protein activation (Supplementary
Figure 6).
IRL1620 induces a similar but slightly different rearrange-
ment of the hydrogen bonding network in the intermembrane
part (Fig. 5e). Due to the smaller inward shift of the
extracellular portion of TM6, the downward shift of the
W3366.48 side chain is smaller in the IRL1620-bound
structure, and it still forms a water-mediated hydrogen bond
with the D1472.50 side chain. Consequently, the D1472.50 side
chain forms a direct hydrogen bond with N3787.45, thereby
preventing the downward motion of N3787.45 and the
hydrogen bond formation between N3787.45 and W3366.48.
Overall, the downward motions of the W3366.48 and N3787.45
side chains are only moderate, as compared to those in the ET-
3-bound structure, and the hydrogen-bonding network invol-
ving D1472.50, W3366.48, and N3787.45 is partially preserved in
the IRL1620-bound structure (Fig. 5e, and Supplementary
Figure 7c). Accordingly, in the IRL1620-bound structure, the
position of the “transmission switch” residue F3326.44 is in
between those of the active (ET-3-bound) and inactive (K-
8794-bound) structures (Fig. 5f). This intermediate position of
F3326.44 should partly prevent the outward displacement of












































































Fig. 4 Conservation of the IRL1620 binding site. a Sequence conservation
between ETA and ETB, mapped onto the IRL1620-bound structure. The
upper panel shows the conservation of the residues constituting the
IRL1620 binding site. Conserved and non-conserved residues are coloured
orange and grey, respectively. The ETB receptor is shown as ribbons, and
the residues involved in IRL1620 binding are shown as sticks. Moreover,
W167 and P168 in ECL1 are shown as sticks. The lower panel shows the
conservation of the ECL1-ECL2 interface. b Alignment of the amino acid
sequences of the human ETB and ETA receptors, focused on ECL2. c
Concentration-response curves of AP-TGFα release response upon ET-1 or
IRL1620 treatments of HEK293 cells expressing the wild-type (WT) ETB
receptor or the L252H I254T double mutant. Symbols and error bars are
means and s.e.m. of six independent experiments, each performed in
triplicate
Table 4 Pharmacological parameters for the L252H I254T
double mutant
ETB-WT (n= 6) L252H/I254T (n= 6)
Ligand EC50, nM (pEC50 ± SEM) EC50, nM (pEC50 ± SEM)
ET-1 0.15 (9.82 ± 0.11) 0.14 (9.85 ± 0.11, NS)
IRL1620 0.14 (9.85 ± 0.09) 0.32 (9.50 ± 0.07*)
pEC50 value that significantly differs from the wild-type is denoted by an asterisk
*P < 0.05 as compared with ETB-WT, Sidak's multiple comparisons test
NS Not significant
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activation. Overall, the smaller inward shift of the extracellular
potion of TM6 and the preserved interactions at the receptor
core account for the partial agonistic activity of IRL1620
(Fig. 6).
Discussion
Previous studies have suggested that the α-helical and C-terminal
regions of endothelins are critical elements for receptor activa-
tion33,36,37, whereas the N-terminal region is only responsible for
the ETR selectivity6. Indeed, the N-terminal region-truncated
analogue IRL1620 has similar EC50 values, as compared with ET-
117. However, our pharmacological experiments for the first time
proved that IRL1620 functions as a partial agonist for the ETB
receptor, rather than a full agonist, suggesting the participation of
the N-terminal region in the activation process of the ETB
receptor. To clarify the receptor activation mechanism, we
determined the crystal structures of the human ETB receptor in
complex with ET-3 and IRL1620. The high-resolution structure
of the ET-3-bound ETB receptor revealed that the large inward
motions of the extracellular portions of TMs 2, 6, and 7 disrupt
the water-mediated hydrogen bonding network at the receptor
core (Fig. 5d, and Supplementary Figure 7a, b). The IRL1620-
bound ETB structure revealed that the IRL1620-induced inward
motions of TMs 6 and 7 are smaller by about 1 Å, as compared
with those caused by ET-3 (Fig. 5b, c). Despite the lower reso-
lution of the IRL1620-bound structure, the 2Fo – Fc map shows
different rearrangement of water molecules and amino acid
residues in the receptor core, in which the hydrogen-bonding
network is partially preserved (Fig. 5e, and Supplementary Fig-
ure 7c). This preserved network, together with the smaller inward
motion of TM6, may prevent cytoplasmic outward motion of
TM6 that occurs upon G-protein binding. These observations
suggest that the interactions between the N-terminal regions of
endothelins and TM6 also participate in receptor activation, while
the extensive interactions of the α-helical and C-terminal regions
with the receptor primarily contribute to this process (Supple-
mentary Figure 3c). This activation mechanism is different from
that of the small-molecule activated GPCRs (e.g., β2 adrenaline
and M2 muscarinic acetylcholine receptors), in which only a
small number of hydrogen-bonding interactions between the
agonist and the receptor induce receptor activation, by affecting
the receptor dynamics38,39.
D2.50 is one of the most conserved residues among the class A
GPCRs (90%). Recent high-resolution structures have revealed
that a sodium ion coordinates with D2.50 and forms a water-
mediated hydrogen bonding network in the intermembrane
region, which stabilizes the inactive conformation of the recep-
tor40, and its collapse leads to receptor activation. Our previous
2.2 Å resolution structure of the K-8794-bound ETB receptor
revealed that a water molecule occupies this allosteric sodium site
and participates in the extensive hydrogen-bonding network,
instead of a sodium ion28 (Supplementary Figure 7a), and this
hydrogen-bonding network is collapsed in the 2.8 Å resolution
structure of the ET-1-bound ETB receptor, indicating its invol-
vement in the receptor activation27. Nevertheless, the precise
K8794 ET-3 IRL1620a b c
d e f
Fig. 5 Comparison of the K8794, ET-3, and IRL1620-bound structures. a–c Comparison of the K-8794-bound inactive (PDB 5X93), IRL1620-bound partially
active, and ET-3-bound active ETB structures, coloured turquoise, orange, and orange-red, respectively. The ETB receptors and agonist peptides are shown
as ribbon models, viewed from the intracellular side (a), the extracellular side (b), and the membrane plane (c). The cytoplasmic cavity for the G-protein
binding is still hindered by the inwardly-oriented TM6 in the ET-3 and IRL1620-bound receptors, representing the inactive conformations. This is consistent
with the notion that the fully active conformation is only stabilized when the G-protein is bound, as shown in the previous nuclear magnetic resonance
(NMR) and double electron–electron resonance (DEER) spectroscopy study38. d–f Superimposition of the ETB structures bound to K-8794 and ET-3 (d), K-
8794 and IRL1620 (e), and K-8794, IRL1620, and ET-3 (f), focused on the intermembrane parts. The receptors are shown as ribbons, and the side chains of
N1191.50, D1472.50, F3326.44, W3366.48, and N3787.45 are shown as sticks with transparent surface representations. Waters are shown as red spheres. The
dashed lines show hydrogen bonds coloured in the respective structures. The arrows show the structural changes on ligand binding
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rearrangement of this network still remained to be elucidated, due
to the limited resolution. The current 2.0 Å resolution structure of
the ET-3-bound ETB receptor revealed that the collapse of the
water-mediated interaction between W3366.48 and D1472.50 is
critical for receptor activation (Fig. 5d). This network is still
partly preserved in the IRL1620-bound structure (Fig. 5e), thus
preventing the transition to the fully active conformation upon
G-protein coupling (Fig. 6). W6.48 is also highly conserved
among the class A GPCRs (71%)41, and the association between
W6.48 and D2.50 has a critical role in the GPCR activation
process, as shown in the previous nuclear magnetic resonance
(NMR) study of the adenosine A2A receptor42. Given the
importance of W3.36 and D2.50 in the activation of GPCRs, our
proposed model of the partial receptor activation by IRL1620 is
consistent with the previous functional analyses of GPCRs. To
date, the β1 adrenergic receptor is the only receptor for which
agonist- and partial agonist-bound structures were reported43.
However, these structures are both stabilized in inactive con-
formations by the thermostabilizing mutations and thus revealed
only slight differences (Supplementary Figure 8). Therefore, our
study provides the first structural insights into the partial acti-
vation of class A GPCRs.
Our current study further suggests possible improvements in
clinical studies using ETB-selective agonists. IRL1620 is the
smallest among the ETB-selective agonists, and thus is expected to
be useful for the treatment of cancers and other diseases18–
22,24,25. While its effectiveness has been proven in rat experi-
ments, a recent phase 2 study has failed26, and thus further
improvement of IRL1620 is required for clinical applications. Our
cell-based assays and structural analysis revealed the partial
agonistic effect of IRL1620 on the ETB receptor in the G-protein
coupling and β-arrestin recruitment activities, suggesting the
possible tuning of its efficacy. The development of ETB-selective
agonists by fine-tuning their G-protein activation and/or β-
arrestin recruitment activities might be beneficial for clinical
applications.
Methods
Expression and purification. We used the thermostabilized receptor ETB-Y5-T4L.
as previously established (Supplementary Table 1). In brief, the haemagglutinin
signal peptide followed by the Flag epitope tag was added to the N-terminus, and a
tobacco etch virus (TEV) protease recognition sequence was introduced between
G57 and L66. The C-terminus was truncated, and three cysteine residues were
mutated to alanine (C396A, C400A, and C405A). To facilitate crystallogenesis, T4
lysozyme (C54T and C97A) was introduced into intracellular loop 3.
The ETB-Y5-T4L was subcloned into a modified pFastBac vector, with the
resulting construct encoding a TEV cleavage site followed by a GFP-His10 tag at the
C-terminus. The recombinant baculovirus was prepared using the Bac-to-Bac
baculovirus expression system (Invitrogen). Sf9 insect cells (Invitrogen) were
infected with the virus at a cell density of 4.0 × 106 cells per millilitre in Sf900 II
medium, and grown for 48 h at 27 °C. The cells were disrupted by sonication, in
buffer containing 20 mM Tris–HCl, pH 7.5, and 20% glycerol. The membrane
fraction was collected by ultracentrifugation, and solubilized in buffer, containing
20 mM Tris–HCl, pH 7.5, 200 mM NaCl, 1% DDM, 0.2% cholesterol
hemisuccinate, and 2 mg/ml iodoacetamide, for 1 h at 4 °C. The insoluble material
was removed by ultracentrifugation at 180,000 × g for 20 min, and incubated with
TALON resin (Clontech) for 30 min. The resin was washed with ten column
volumes of buffer, containing 20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 0.1%
LMNG, 0.01% CHS, and 15 mM imidazole. The receptor was eluted in buffer,
containing 20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 0.01% LMNG, 0.001% CHS,
and 200 mM imidazole. TEV protease was added to the eluate, and the mixture was
dialysed against buffer (20 mM Tris–HCl, pH 7.5, and 500 mM NaCl). The cleaved
GFP and the protease were removed with Co2+-NTA resin. The flowthrough was
concentrated and loaded onto a Superdex200 10/300 Increase size-exclusion
column, equilibrated in buffer containing 20 mM Tris–HCl, pH 7.5, 150 mM NaCl,
0.01% LMNG, and 0.001% CHS. Peak fractions were concentrated to 40 mgml−1
using a centrifugal filter device (Millipore 50 kDaMW cutoff), and frozen until
crystallization. ET-3 or IRL1620 was added to a final concentration of 100 μM,
during the concentration.
Crystallization. The purified receptors were reconstituted into molten lipid
(monoolein and cholesterol 10:1 by mass) at a weight ratio of 1:1.5 (protein:lipid).
The protein-laden mesophase was dispensed into 96-well glass plates in 30 nl drops
and overlaid with 800 nl precipitant solution, using an LCP dispensing robot
K8794-inactive IRL1620-partial active ET-3-active
Fig. 6 Receptor activation by ET-3 and partial activation by IRL1620. Schematic representations of receptor activation by ET-3 and partial activation by
IRL1620. TM6, TM7, and H8 are highlighted. The residues involved in the signal transduction (N1.50, D2.50, F6.44, W6.48, and N7.45) are represented
with sticks. Hydrogen bonds are indicated by black dashed lines. Arrows indicate the conformational changes in TM6 and TM7 upon ET-3 and IRL1620
binding. In the K-8794-bound structure (left), a water-mediated hydrogen bonding network among D1472.50, W3366.48, and N3787.45 stabilizes the
inactive conformation of the receptor. ET-3 binding disrupts this network and propagates the structural change of the transmission switch comprising
F3326.44 and W3366.48 (middle), leading to the outward movement of TM6 upon G-protein coupling. In the IRL1620-bound structure (right), the water-
mediated hydrogen-binding network is preserved, thus preventing the outward movement of TM6 upon G-protein coupling
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(Gryphon, Art Robbins Instruments)44,45. Crystals of ETB-Y5-T4L bound to ET-3
were grown at 20 °C in the precipitant conditions containing 25% PEG500DME,
100 mM MES-NaOH, pH 6.0, and 100 mM ammonium citrate tribasic. The
crystals of ETB-Y5-T4L bound to IRL1620 were grown in the precipitant conditions
containing 20–25% PEG500DME, 100 mM sodium citrate, pH 5.0, and 100 mM
(NH4)2SO4 or NH4Cl. The crystals were harvested directly from the LCP using
micromounts (MiTeGen) or LithoLoops (Protein Wave) and frozen in liquid
nitrogen, without adding any extra cryoprotectant.
Data collection and structure determination. X-ray diffraction data were col-
lected at the SPring-8 beamline BL32XU with 1 × 10 to 8 × 25 μm2 (width × height)
micro-focused beams and an EIGER X 9M detector (Dectris). For the IRL1620
data, we manually collected 68 data sets (10°–180° per crystal), and the collected
images were automatically processed with KAMO31 (https://github.com/
keitaroyam/yamtbx). Each data set was indexed and integrated with XDS46 and
then subjected to a hierarchical clustering analysis based on the unit cell parameters
using BLEND47. After the rejection of outliers, 46 data sets were finally merged
with XSCALE46. From the ET-3-bound crystals, various wedge datasets (3–180°)
per crystal were mainly collected with the ZOO system, an automatic data-
collection system developed at SPring-8.The loop-harvested microcrystals were
identified by raster scanning and subsequently analysed by SHIKA48. The collected
images were processed in the same manner, except that correlation coefficient-
based clustering was used instead of BLEND, and finally 483 datasets were merged.
The ET-3-bound structure was determined by molecular replacement with PHA-
SER49, using the ET-1-bound ETB structure (PDB 5GLH). Subsequently, the model
was rebuilt and refined using COOT50 and PHENIX51, respectively. The IRL1620-
bound structure was determined by molecular replacement, using the ET-1-bound
ETB structure, and subsequently rebuilt and refined as described above. The final
model of ET-3-bound ETB-Y5-T4L contained residues 86–303 and 311–403 of
ETB, all residues of T4L, ET-3, 12 monoolein molecules, a citric acid, and
175 water molecules. The final model of IRL1620-bound ETB-Y5-T4L contained
residues 87–303 and 311–402 of ETB, all residues of T4L, IRL1620, 3 monoolein
molecules, 4 sulfate ions, a citric acid, and 59 water molecules. The model
quality was assessed by MolProbity52. Figures were prepared using CueMol (http://
www.cuemol.org/en/)
TGFα shedding assay. The TGFα shedding assay53, which measures the activation
of Gq and G12 signalling, was performed as described previously28. Briefly, a pCAG
plasmid encoding a codon-optimized ETB construct (Supplementary Table 2) with
an internal FLAG epitope tag or a full-length human ETA construct with an
internal FLAG epitope tag cloned from cDNA was prepared. Double mutant
L252H I254T was generated by Quickchange PCR (Supplementary Table 3). These
plasmids were transfected, together with a plasmid encoding alkaline phosphatase
(AP)-tagged TGFα (AP-TGFα), into HEK293A cells by using a polyethylenimine
(PEI) transfection reagent (1 µg ETR plasmid, 2.5 µg AP-TGFα plasmid and 25 µl
of 1 mg/ml PEI solution per 10-cm culture dish). After a one day culture, the
transfected cells were harvested by trypsinization, washed, and resuspended in 30
ml of Hank’s Balanced Salt Solution (HBSS) containing 5 mM HEPES (pH 7.4).
The cell suspension was seeded in a 96 well plate (cell plate) at a volume of 90 μl
per well and incubated for 30 min in a CO2 incubator. Test compounds, diluted in
0.01% bovine serum albumin (BSA) and HEPES-containing HBSS, were added to
the cell plate at a volume of 10 µl per well. After a 1 h incubation in the CO2
incubator, the conditioned media (80 μl) was transferred to an empty 96-well plate
(conditioned media (CM) plate). The AP reaction solution (10 mM p-
nitrophenylphosphate (p-NPP), 120 mM Tris–HCl (pH 9.5), 40 mM NaCl, and 10
mM MgCl2) was dispensed into the cell plates and the CM plates (80 µl per well).
The absorbance at 405 nm (Abs405) of the plates was measured, using a microplate
reader (SpectraMax 340 PC384, Molecular Devices), before and after a 1-h incu-
bation at room temperature. AP-TGFα release was calculated as described pre-
viously28. The AP-TGFα release signals were fitted to a four-parameter sigmoidal
concentration-response curve, using the Prism 7 software (GraphPad Prism), and
the pEC50 (equal to −Log10 EC50) and Emax values were obtained.
β-arrestin recruitment assay. For the NanoBiT-β-arrestin recruitment assay54, a
receptor construct was designed to fuse the small fragment (SmBiT) of the
NanoBiT complementation luciferase to the C-terminus of the ETR construct with
a 15-amino acid flexible linker (GGSGGGGSGGSSSGG). A PCR-amplified ETR
fragment and an oligonucleotide-synthesized SmBiT were assembled and inserted
into the pCAGGS mammalian expression plasmid (a kind gift from Dr. Jun-ichi
Miyazaki, Osaka University), using a NEBuilder HiFi DNA Assembly system (New
England Biolabs). A β-arrestin construct was generated by fusing the large frag-
ment (LgBiT), with nucleotide sequences gene-synthesized with mammalian codon
optimization (Genscript), to the N-terminus of human β-arrestin1 (βarr1) with the
15-amino acid linker. The R393E and R395E mutations, which were shown to
abrogate AP-2 binding and thus are defective in internalization55, were introduced
into LgBiT-βarr1 to facilitate the formation of the ETR-βarr1 complex. The
plasmid encoding the ETB-SmBiT construct or the ETA-SmBiT construct was
transfected, together with the plasmid encoding the internalization-defective
LgBiT-βarr1, into HEK293A cells by the PEI method (1 µg ETR-SmBiT plasmid,
0.5 µg LgBiT-βarr1 plasmid, and 25 µl of 1 mg/ml PEI solution per 10-cm culture
dish). After a one-day culture, the transfected cells were harvested with EDTA-
containing Dulbecco’s phosphate-buffered saline and resuspended in 10 ml of
HBSS containing 5 mM HEPES and 0.01% BSA (BSA-HBSS). The cell suspension
was seeded in a 96-well white plate at a volume of 80 μl per well and loaded with
20 µl of 50 µM coelenterazine (Carbosynth), diluted in BSA-HBSS. After an
incubation at room temperature for 2 h, the background luminescent signals were
measured using a luminescent microplate reader (SpectraMax L, Molecular Devi-
ces). Test compounds (6×, diluted in BSA-HBSS) were manually added to the cells
(20 µl). After ligand addition, the luminescent signals were measured for 15 min at
20-s intervals. The luminescent signal was normalized to the initial count, and the
fold-change values over 5–10 min after ligand stimulation were averaged. The fold-
change β-arrestin recruitment signals were fitted to a four-parameter sigmoidal
concentration–response, and the pEC50 and Emax values were obtained as described
above.
Data availability
The atomic coordinates and structure factors of the ETB receptor have been
deposited in the Protein Data Bank (PDB) (https://www.rcsb.org/) with accession
codes 6IGK (ET3-bound) and 6IGL (IRL1620-bound). The raw X-ray diffraction
images are also available at SBGrid Data Bank (https://data.sbgrid.org/) with IDs
611 and 612, respectively. Other data are available from the corresponding authors
upon reasonable request.
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